글로벌 광선공포증 약물 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 광선공포증 약물 시장

광공포증 약물 시장은 2021년에서 2028년까지의 예측 기간 동안 13.95%의 잠재적인 시장 성장률을 얻을 것으로 예상됩니다. 많은 제약 산업에서 수행 중인 진행 중인 임상 시험 연구의 증가는 광공포증 약물 시장 성장을 확대하는 중요한 요인입니다.

광공포증은 광과민증으로도 알려져 있으며, 사람들이 빛을 참을 수 없는 유형의 상태입니다. 직사광선이나 램프 및 가로등과 같은 인공 광원일 수 있습니다. 광과민증은 편두통 및 건조한 눈과 같은 기저 질환의 증상이거나 백색증이라고 하는 눈 색소 결핍으로 인해 발생할 수도 있습니다. 편두통 및 건조한 눈 증후군이 있는 거의 모든 환자는 두통 발작 중에 광공포증을 보고했으며, 그 결과 삶의 질과 사회적 기능에 영향을 미쳤습니다. 광공포증이 있는 환자는 눈의 통증이나 불편함 때문에 빛을 피합니다.

특정 독소에 대한 노출 증가 또는 환경 변화로 인해 편두통 상태가 증가하여 시장 성장이 촉진될 수 있으며, 새로운 제형과 새로운 복용 형태의 빠른 채택 증가, 전 세계 광선 공포증 유병률 증가, 전 세계 광선 공포증 인구 증가 , 편두통 및 건조한 눈과 같은 광선 공포증 상태와 관련된 위험 치료에 사용되는 약물의 등장은 광선 공포증 약물 시장 성장을 주도하는 몇 가지 중요한 요인입니다. 또한 시장에서의 연구 개발 활동 증가, 의료 결과 증가, 신흥 경제권의 수요 증가는 2021-2028년 예측 기간 동안 광선 공포증 약물 시장에 새로운 기회를 창출할 것입니다.

However, effective treatment is either unavailable or unaffordable and inadequate knowledge about photophobia in some developing countries are the major factors among others acting as restraints, while patent expiry from many companies and introduction of generic drugs of branded version will further challenge the photophobia drug market in the forecast period mentioned above.

This photophobia drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the photophobia drug market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Photophobia Drug Market Scope and Market Size

The photophobia drug market is segmented on the basis of causes type, treatment type, mechanism of action type, route of administration and end-user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of causes type, the photophobia drug market is segmented into migraine, scleritis, corneal ulcer, conjunctivitis, dry eyes and others.
• Based on treatment type, the photophobia drug market is segmented into medication and surgery.
• Based on mechanism of action type, the photophobia drug market is segmented into serotonin (5-HT1B/1D) receptor agonist (triptan), calcitonin gene-related peptide receptor antagonist, acetylcholine release inhibitor and others. Serotonin (5-HT1B/1D) receptor agonist (triptan) has been further segmented into sumatriptan. Calcitonin gene-related peptide receptor antagonist has been further segmented into fremanezumab, erenumab and galcanezumab. Acetylcholine release inhibitor has been further segmented into onabotulinumtoxina.
• Based on route of administration, the photophobia drug market is segmented into oral, topical and injectable.
• The photophobia drug market is also segmented on the basis of end-user into hospitals, homecare, specialty clinics and others.

Photophobia Drug Market Country Level Analysis

The photophobia drug market is analysed and market size information is provided by country, causes type, treatment type, mechanism of action type, route of administration and end-user as referenced above.

The countries covered in the photophobia drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the photophobia drug market due to increase in the rapid adoption of newer formulations and novel dosage forms, increase in the prevalence rate of photophobia worldwide and rise in the population of photophobia worldwide and emergence of drugs used in the treatment of risk associated with photophobia condition such as migraine and dry eyes in this region. Asia-Pacific is the expected region in terms of growth in photophobia drug market due to rise in the rapid adoption of newer formulations and novel dosage forms in this region.

The country section of the photophobia drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The photophobia drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Photophobia Drug Market Share Analysis

The photophobia drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to photophobia drug market.

광선공포증 약물 시장 보고서에서 다루는 주요 기업은 Sun Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Allergan, Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson Services, Inc., Bausch Health, Merck & Co., Inc, Alder Biopharmaceuticals Inc, Zogenix, RedHill, Eisai Co., Ltd, Ionis Pharmaceuticals, Inc, Biofrontera AG, Biohaven Pharmaceuticals, Achelios 및 Dr. Reddy's Laboratories Ltd 시장 점유율 데이터는 글로벌, 북미, 남미, 유럽, 아시아 태평양(APAC) 및 중동 및 아프리카(MEA)에 대해 별도로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.

SKU-44709